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Role of kidney-specific organic anion transporters in the uri- doses and of rheumatoid arthritis at relatively low doses
nary excretion of methotrexate. [1–3]. Because urinary excretion represents the major
Background. High-dose folinic acid is used to accelerate route of elimination of methotrexate from the body, itmethotrexate elimination to avoid renal toxicity of the drug.
reaches high concentrations in the renal tubules to causeThe present study was carried out to examine the role of the
nephrotoxicity, a severe problem associated with metho-renal organic anion transporters OAT-K1 and OAT-K2 in the
urinary excretion of methotrexate, especially in the methotrex- trexate therapy [4, 5]. Several studies have reported the
ate-folinic acid rescue therapy. pharmacokinetics and/or toxicokinetics of methotrexate
Methods. Madin-Darby canine kidney cells stably express- during renal impairment, and showed that methotrexateing OAT-K1 and OAT-K2 were used for the in vitro transport
toxicity is caused by the length of exposure rather thanstudy; 5/6 nephrectomized rats were used to detect changes in
the serum level of methotrexate achieved [6, 7].mRNA expression levels of OAT-K1 and OAT-K2 and to
evaluate methotrexate pharmacokinetics under conditions of To reduce the toxicity of methotrexate, folinic acid res-
renal insufficiency. cue is used [2, 8]. Folinic acid induces repletion of intra-
Results. Methotrexate efflux mediated by these transporters cellular reduced folates and the resumption of tetrahy-in stable transfectants was stimulated in the presence of extra-
drofolic acid-dependent macromolecular synthesis [1].cellular folic acid and folinic acid, suggesting that they could
In addition, treatment with folinic acid accelerates theserve as anion exchangers to enhance the apical efflux of metho-
trexate. The mRNA expression levels of OAT-K1 and OAT-K2 renal excretion of methotrexate, reducing the duration
were markedly diminished after 5/6 nephrectomy, but those of of exposure [9]. Many studies have shown that tubular
multidrug resistance associated protein 2, which could transport secretion of methotrexate is mediated by an organic anionmethotrexate, were maintained. Renal clearance of metho-
transport system [10, 11], and recent molecular studiestrexate was markedly decreased in 5/6 nephrectomized rats com-
have identified several candidates for organic anion trans-pared with that in sham-operated rats. Additional folinic acid
treatment resulted in a significant increase in methotrexate porters that can mediate methotrexate transport in the
renal clearance in sham-operated rats but not in 5/6 nephrecto- kidney, such as organic anion transporter-1 (OAT1) [12],
mized rats. OAT2 [13], multidrug resistance associated protein 1Conclusions. The decreased expressions of OAT-K1 and
(MRP1) [14], MRP2 [14, 15], and the kidney-specific or-OAT-K2 may be attributable to the longer exposure to metho-
ganic anion transporters OAT-K1 [16] and OAT-K2 [17].trexate and ineffective folinic acid rescue. In terms of contribut-
ing to patient safety, renal clearance of methotrexate, especially Because methotrexate is a folic acid derivative, pharma-
folinic acid-stimulated tubular secretion of the drug via these cokinetic drug interactions with folinic acid may occur;
transporters, would be a key factor in methotrexate therapy. however, no studies have examined this action.
Rat OAT-K1 and OAT-K2, both of which were iso-
lated in our laboratory, are expressed specifically in the
The antifolic acid methotrexate has been widely used brush-border membranes of the renal proximal straight
in the treatment of acute lymphocytic leukemia at high tubules [17, 18]. Functional analysis revealed that both
of these transporters are involved in methotrexate trans-
port and mediate bidirectional transport of substratesKey words: OAT-K1 and -K2, folinic acid rescue, renal impairment,
[16, 17, 19]. Recently, trans-stimulation effects of extra-nephrotoxicity, antifolic acid, acute lymphocytic leukemia, rheumatoid
arthritis. cellular organic anions on the efflux of methotrexate via
OAT-K1 have been reported [20], suggesting that it couldReceived for publication October 31, 2000
play a part in detoxication of hydrophobic organic anionsand in revised form March 14, 2001
Accepted for publication March 16, 2001 from tubular epithelial cells into urine. However, their
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mains to be elucidated. Moreover, the alteration of metho- Renal histology and analytical methods
trexate pharmacokinetics and the contribution of these Kidneys were fixed in ethyl Carnoy’s solution and were
transporters under renal failure have not been clarified. stained with periodic acid-Schiff reagent (PAS) [22].
The aim of the present study was to examine the con- The concentrations of creatinine and blood urea nitro-
tribution of OAT-K1 and OAT-K2 in the renal handling gen (BUN) were measured using the Jaffe´ method and the
of methotrexate, especially during methotrexate-folinic urease-indophenol method with commercial kits (Wako).
acid rescue, using the 5/6 nephrectomized rat kidney. Urinary albumin was assessed using an enzyme-linked
immunosorbent assay (ELISA) kit (NEPHRAT II; Exo-
cell, Inc., Philadelphia, PA, USA).METHODS
Materials Synthesis of cRNA probes
[3,5,7-3H(N)]Methotrexate disodium salt (555 GBq/ By polymerase chain reaction (PCR) amplification of
mmol), [3,5,7,9-3H]folic acid diammonium salt (1232 the cDNAs OAT-K1/pSPORT1 and OAT-K2/pSPORT1
GBq/mmol), and [3,5,7,9-3H] (6S)-leucovorin diam- [17], fragments corresponding to nucleotides 1 to 553 and
monium salt (folinic acid; 962 GBq/mmol) were obtained 1 to 433 of the OAT-K1 and OAT-K2 mRNA sequences
from Moravek Biochemicals, Inc. (Brea, CA, USA). Un- were isolated, respectively. The PCR profile was as fol-
labeled methotrexate was purchased from Wako Pure lows: 94C for one minute, 60C for one minute, 72C
Chemical Industries (Osaka, Japan). All other chemicals for two minutes, 35 cycles. The primers used were T7
used were of the highest purity available. promoter primer as the sense strand and 5-CCGCGG
CCGCCACAAGAAGCTGTTTGAGGA-3 as the anti-Transport study with cell monolayers
sense strand with a NotI site. The amplified fragments
Madin-Darby canine kidney (MDCK) cells stably ex- were digested with SalI and NotI and subcloned into the
pressing OAT-K1 and OAT-K2, designated MDCK- SalI- and NotI-cut pSPORT1 (Life Technologies, Inc.,
OAT-K1 and MDCK-OAT-K2 [17], were used through- Rockville, MD, USA). The resulting plasmids were
out the transport study.
named 5OAT-K1/pSPORT1 and 5OAT-K2/pSPORT1.
The cellular uptake of drugs was measured using mono-
As a control, a PCR-amplified 594-nucleotide fragment
layer cultures grown in 12-well microplates. The incuba-
for GAPDH (positions 131 to 724) [23] was also sub-tion medium for uptake experiments was Dulbecco’s phos-
cloned into pPCR-Script Amp SK() (Stratagene, Laphate-buffered saline (PBS; 137 mmol/L NaCl, 3 mmol/L
Jolla, CA, USA), and the resulting plasmid was namedKCl, 8 mmol/L Na2HPO4, 1.5 mmol/L KH2PO4, 1 mmol/L 5GAPDH/pPCR-Script. The DNA sequences of theCaCl2 and 0.5 mmol/L MgCl2, pH 7.4) containing 5 cloned DNAs were verified and found to be identical tommol/L d-glucose (uptake buffer). Experimental proce-
published sequences in the GeneBank/EBI Data Bankdures were performed as described previously [20]. After
by analysis in an automated 373 Prism DNA sequencerthe incubation, the cells were lysed in a 0.5 N NaOH
(Applied Biosystems, Norwalk, CT, USA).solution, and then the radioactivity in aliquots was deter-
After linearization of the constructed cDNAs 5OAT-mined in 5 mL of ACSII (Amersham Int., Buckingham-
K1/pSPORT1, 5OAT-K2/pSPORT1 and 5GAPDH/shire, UK). The protein content of the solubilized cells
pPCR-Script by digestion with SalI, antisense OAT-K1,was determined by the method of Bradford [21] using
OAT-K2, and GAPDH cRNA labeled with [-32P]CTPthe Bio-Rad Protein Assay kit (Bio-Rad, Hercules, CA,
(800 Ci/mmol; Amersham Int.) were generated by in vitroUSA) with the bovine c-globulin as a standard.
transcription (Promega Co., Madison, WI, USA). The
Animal surgery antisense cRNA probes were purified using an E.Z.N.A.
RNA Probe Purification Kit (Omega Biotek Inc., Dora-For ablation of the renal mass, male Wistar albino rats
ville, GA, USA).(200 to 220 g) were anesthetized with sodium pentobarbi-
tal (40 mg/kg), and the kidneys were exposed under
RNA extraction and RNase protection assayaseptic conditions via a ventral abdominal incision. The
Rat kidney total RNA was extracted using TRIZOLright kidneys were removed, and the posterior and ante-
Reagent (Life Technologies) and resuspended in 100%rior apical segmental branches of the left renal artery
formamide until use. RNase protection assay was per-were individually ligated. The abdominal incision was
formed as described previously [24], with some modi-closed with 4-0 silk sutures [22]. In the sham-operated
fications. The [-32P]-labeled OAT-K1, OAT-K2, andanimals, the peritoneal cavity was exposed, and both
GAPDH antisense probes (3  104 cpm/tube) and 2 gkidneys were gently manipulated. After surgery, animals
of total RNA were hybridized in hybridization bufferwere allowed free access to water and food. The animal
[40 mmol/L PIPES, pH 6.4, 1 mmol/L ethylenediamine-experiments were performed in accordance with the
Guidelines for Animal Experiments of Kyoto University. tetraacetic acid (EDTA), 0.4 mol/L sodium acetate and
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Table 1. Nucleotide sequences of the polymerase chain reaction (PCR) primers, the expected sizes of the amplified products,
and cycle numbers of PCR reactions
Primers Positionsa Product Cycles
SGLT1
Sense 5-ATGGACAGTAGCACCTTGAGCC-3 170-191 499 bp 32
Antisense 5-TAGCCCCAGAGAAGATGTCTGC-3 647-668
SGLT2
Sense 5-CATTGTCTCAGGCTGGCACTGG-3 851-872 460 bp 26
Antisense 5-GGACACTGCCACAATGAACACC-3 1289-1310
MRP2
Sense 5-ACCTTCCACGTAGTGATCCT-3 986-1005 1085 bp 32
Antisense 5-GATTTCCCAGAGCCTACAGT-3 2051-2070
GAPDH
Sense 5-CCTTCATTGACCTCAACTAC-3 131-150 594 bp 26
Antisense 5-GGAAGGCCATGCCAGTGAGC-3 705-724
All of the PCR reactions were performed as described in the Methods section.
a Each position was from the sequence in the GenBank database
80% formamide] by incubating for 10 minutes at 85C, Northern blot analysis
followed by overnight at 45C. The hybridized mixture Five micrograms of rat kidney total RNA were re-
was digested with RNase ONE Ribonuclease (10 U/300 solved by electrophoresis in 1% agarose gels containing
L; Promega) for one hour at 30C to digest single- formaldehyde and transferred onto nylon membranes.
stranded RNA. Samples were extracted with phenol/ After transfer, blots were hybridized at high stringency
chloroform/isoamyl alcohol and then precipitated with [50% formamide, 5  SSPE (20  SSPE; 3 mol/L NaCl,
cold ethanol. Each pellet was dissolved in gel-loading
0.2 mol/L NaH2PO4, 0.02 mol/L EDTA, pH 7.4), 5 buffer (95% formamide, 0.025% xylene cyanol, 0.025%
Denhardt’s solution, 0.2% SDS, and 10 g/mL herringbromophenol blue, 18 mmol/L EDTA, and 0.025% SDS),
sperm DNA (Promega) at 42C] with the SGLT1,heat denatured, and analyzed by electrophoresis on de-
SGLT2, MRP2, and GAPDH cDNA fragment labelednaturing 3.5% polyacrylamide gel containing 8 mol/L
with [-32P]dCTP as probes. Each probe was obtainedurea. Dried gels were exposed to the imaging plates of
by RT-PCR amplification of rat total kidney RNA asa FUJIX BIO-Imaging Analyzer BAS 2000II (Fuji Photo
described previously in this article. The blots wereFilm, Tokyo, Japan).
washed for one hour at 30C in 2  SSC (20  SSC; 3
RT-PCR mol/L NaCl, 0.3 mol/L sodium citrate) containing 0.1%
SDS and were exposed to the imaging plates of a FUJIXOne microgram of rat kidney total RNA was reverse
BIO-Imaging Analyzer BAS 2000II.transcribed (final volume of each reaction was 20 L)
with random primers (100 ng/reaction), using a Super-
In vivo clearance study of methotrexatescript II reverse transcriptase (Life Technologies) and
subjected to RNase H (Life Technologies) digestion. The renal clearance of methotrexate was estimated in
After a tenfold dilution of the reaction mixture with di- 5/6 nephrectomized or sham-operated rats two weeks
ethylpyrocarbonate-treated water (final volume of 200L), after the surgery. Rats were kept in metabolic cages for
PCR was performed. For the reaction of GAPDH, so- determining urine output and urinary level of creatinine
dium/glucose cotransporter (SGLT1) [25], SGLT2 [26], and albumin for 24 hours before the experiment. Blood
and MRP2, 1, 4, 8, and 20 L of the tenfold diluted- samples were collected from a tail vein, and blood gas,
reaction mixture were used, respectively. Following the electrolytes were measured by the i-STAT Portable
denaturing of the single-stranded DNA at 95C for three Clinical Analyzer (i-STAT Co., East Windsor, NJ, USA)
minutes, the PCR was performed: 94C for one minute, as described elsewhere [28]. The in vivo clearance study
55C for one minute, and 72C for 1.5 minutes, 26 to 32
was performed as follows. Sham-operated and 5/6 ne-cycles. GAPDH was used as internal control. The prim-
phrectomized rats were anesthetized with sodium pento-ers used for MRP2 were identical to those used for semi-
barbital (40 mg/kg). Catheters were inserted into thequantitative RT-PCR in other laboratories [27]. Primer
left femoral artery and the right femoral vein for bloodsequences, positions, and expected sizes of the PCR
sampling and drug administration, respectively. Urineproducts and number of PCR cycles are summarized in
was collected from the urinary bladder catheterized afterTable 1. The amplified PCR products were separated in
a suprapubic incision. The loading dose of 1.7 mol/kg1% agarose gels and stained with ethidium bromide. The
methotrexate required to provide a plasma concentra-relative amounts of band in each reaction were deter-
tion equivalent to that at steady-state was administeredmined densitometrically using NIH Image 1.61 (National
Institutes of Health, Bethesda, MD, USA). through the femoral vein. Then methotrexate was contin-
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uously infused (4.4 nmol/min) over a period of 30 min- mol/L, 3.7 kBq/mL) was used to estimate the extracellu-
lar trapping of [3H]methotrexate. Thereafter, each sliceutes for equilibration. Thereafter, renal clearance was
determined three times—at 30 to 40 minutes, 40 to 50 was rapidly removed from the flask, washed twice in 5 mL
of ice-cold incubation medium, blotted on filter paper,minutes, and 50 to 60 minutes (period 1)—to confirm
that the plateau was reached. Urine was collected during weighed, and solubilized in 0.5 mL of NCS II (Amer-
sham). The radioactivity was determined in 5 mL of ACSthese periods and blood was obtained at the midpoint
of urine collection. Creatinine clearance was simultane- II (Amersham) by liquid scintillation counting.
ously monitored during these periods. The effects of folinic
Statistical analysisacid on renal clearance of methotrexate were investigated
as follows. After determining renal clearance in the ab- Data were analyzed statistically by one-way analysis
of variance followed by Fisher’s t test. Calculations weresence of the concurrent drug, folinic acid was adminis-
tered intravenously and incorporated into the infusion performed using the statistical software package Stat
View 4.11 (Abacus Concepts, Berkeley, CA, USA). Prob-solution. The priming and maintenance doses were 25
mol/kg and 65 nmol/min, respectively. Following equili- ability values of less than 5% were considered significant.
bration for another 30 minutes, renal clearance of metho-
trexate was determined as described previously in this
RESULTS
article (period 2).
Methotrexate efflux via OAT-K1 and OAT-K2 in the
stable transfectantsAnalytical methods and data analysis
The concentration of methotrexate in plasma and To confirm the methotrexate-folinic acid exchange via
OAT-K1 and OAT-K2, their characteristics of methotrex-urine was measured by a fluorescence polarizing immu-
noassay on a TDx instrument (Dainabot Laboratories, ate efflux using stable transfectants were examined fur-
ther. Efflux of [3H]methotrexate from MDCK-OAT-K1Tokyo, Japan).
The plasma unbound fraction of methotrexate was (Fig. 1A) and MDCK-OAT-K2 (Fig. 1B) cells was stimu-
lated in the presence of inwardly directed gradients ofdetermined by an ultrafiltration method using the Micro-
partition System (MPS-1; Amicon, Cambridge, MA, unlabeled methotrexate and folinic acid. In addition, the
accumulation of [3H]folic acid (Fig. 1 C, D) and [3H]foli-USA). Briefly, an adequate volume of blood was taken
from sham-operated and 5/6 nephrectomized rats at the nic acid (Fig. 1 E, F) in the MDCK-OAT-K1 and MDCK-
OAT-K2 cells was markedly enhanced when these cellsend of the in vivo clearance experiments. After centrifu-
gation, plasma was placed in an ultrafiltration device were preloaded with 1 mol/L of unlabeled methotrex-
ate, suggesting that the methotrexate efflux via theseequipped with a YMT ultrafiltration membrane (Ami-
con) and centrifuged at 2000 rpm for three minutes after transporters is stimulated in the presence of extracellular
folic acid derivatives.precentrifugation at 3000 rpm for five minutes to avoid
the nonspecific adsorption of methotrexate to the mem-
Renal histology and biochemical parameters inbrane. The free fraction (fu) of methotrexate was ex-
5/6 nephrectomized ratspressed as the ratio of the methotrexate concentration
in the ultrafiltrate to that in plasma. The surgical procedure of subtotal nephrectomy was
well tolerated by the rats. Figure 2 shows a paraffin-The pharmacokinetic parameters of methotrexate were
calculated on the basis of standard procedures for each embedded section with PAS stain. One week after ne-
phrectomy, there was no structural change between theexperimental period in the clearance studies [29]. Metho-
trexate renal clearance was determined as the urinary sham-operated and 5/6 nephrectomized rats (Fig. 2 A, B).
On the other hand, focal and segmental glomerulone-excretion rate divided by the steady-state plasma un-
bound concentration. phritis and glomerular hypertrophy were found at two
and four weeks (Fig. 2 D, F) compared with those of sham-
Methotrexate uptake by renal slices operated rats (Fig. 2 C, E). However, severe pathological
changes in tubules were not recognized in the periods[3H]Methotrexate (58 nmol/L, 18.5 kBq/mL) uptake
by whole kidney slices from sham-operated and 5/6 ne- examined in this study.
One to four weeks after nephrectomy, the biochemicalphrectomized rats (two weeks after the surgery) was
performed as described previously [30]. Briefly, slices parameters were assessed immediately before sacrifice.
The degree of renal failure was highlighted by elevatedfrom five rats were randomly selected and placed for incu-
bation in a flask containing 2.5 mL of the incubation buffer serum creatinine (Fig. 3A), blood urea nitrogen (BUN;
Fig. 3B), and significant albuminuria (Fig. 3C) compared(120 mmol/L NaCl, 16.2 mmol/L KCl, 1 mmol/L CaCl2,
1.2 mmol/L MgSO4, and 10 mmol/L NaH2PO4/Na2HPO4, with sham-operated rats. Simultaneously, the urinary
creatinine concentration was decreased in 5/6 nephrecto-pH 7.5) with [3H]methotrexate, at 25C for 60 minutes
under an atmosphere of 100% O2. D-[14C]mannitol (1.8 mized rats (Fig. 3D).
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Fig. 1. Trans-stimulation effect of folic acid
derivatives on methotrexate efflux from Madin-
Darby canine kidney (MDCK) organic anion
transporter (OAT)-K1 and MDCK-OAT-K2
cells. MDCK-OAT-K1 (A) and MDCK-OAT-
K2 (B) were preloaded with [3H]methotrexate
at a concentration of 1 mol/L for 30 minutes
at 37C (pH 7.4) and then incubated with up-
take buffer in the absence () or presence of
unlabeled methotrexate and folinic acid ()
at a concentration of 10mol/L. After the incu-
bation, the [3H]methotrexate remaining in the
cells was measured, and the efflux was evalu-
ated by subtracting the remaining value from
the 30-minute accumulation value. MDCK-
OAT-K1 (C and E ) and MDCK-OAT-K2 (D
and F) were preloaded without () or with ()
unlabeled methotrexate at a concentration of
1 mol/L for 30 minutes at 37C (pH 7.4) and
then incubated with 30 nmol/L of [3H]folic
acid (C and D) and 38 nmol/L of [3H]folinic
acid (E and F). After the incubation, the radio-
activity of the solubilized cells was deter-
mined. Each column represents the mean 
SE for three monolayers. *P  0.05; **P 
0.01, significant differences from control.
Detection of OAT-K1 and OAT-K2 mRNA expression levels of each transporter independently. Fig-
expressions in the remnant kidney by the ure 4 shows the nucleotide regions of OAT-K1 and
RNase protection assay OAT-K2 used as probes.
The mRNA expression levels of OAT-K1 (Fig. 5 A, D)Because of the high degree of nucleotide sequence
and OAT-K2 (Fig. 5 B, E) in sham-operated and 5/6conservation among OAT-K1 and OAT-K2 [17], we em-
ployed the RNase protection assay to detect the mRNA nephrectomized rat kidneys are demonstrated, showing the
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Fig. 2. Glomerular and tubular PAS staining of rat kidney tissue. Kidney tissues were obtained at weeks 1 (A and B), 2 (C and D), and 4 (E and F)
from the sham-operated rats (A, C, and E) and 5/6 nephrectomized rats (B, D, and F) (magnification for each photo is 200).
protected fragments of 553 and 433 bases for OAT-K1 and in the remnant kidneys were markedly reduced when
compared with those of sham-operated rats.OAT-K2, respectively. To normalize the RNA loading,
each RNA preparation was analyzed for GAPDH mRNA. Figure 6 shows the semiquantitative analysis of the pre-
viously mentioned data. To normalize the relative mRNAFigure 5 C and F shows the protected fragment of 594
bases for GAPDH. Two and four weeks after the opera- expression levels of OAT-K1 and OAT-K2, the band
intensity for each transporter mRNA was divided by thattion, the band intensities of OAT-K1 and OAT-K2 mRNA
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Fig. 3. Serum creatinine (A), blood urea ni-
trogen (BUN; B), urinary albumin (C) and
urinary creatinine (D) levels in sham-operated
() and 5/6 nephrectomized rats (). Values
are means  SE for 5/6 nephrectomized rats
(N 	 7 to 14) and sham-operated rats (N 	
5 to 8). **P 0.01, significantly different from
sham-operated rats.
Fig. 4. Schematic representation of probes
used for RNase protection assay. OAT-K1
(upper) and OAT-K2 (lower) inserts used as
templates to make probes are shown. Regions
conserved between OAT-K1 and OAT-K2
are indicated by open columns, and specific
regions for each are indicated by closed col-
umns.
Fig. 5. mRNA detection of OAT-K1 (A and
D), OAT-K2 (B and E) and GAPDH (C and
F) in the renal total RNA isolated from sham-
operated and 5/6 nephrectomized rat kidneys
by RNase protection assay. Aliquots of 2g of
total RNA were hybridized with [-32P] OAT-
K1, OAT-K2, or GAPDH RNA probes, and
RNase protection assay was carried out (Meth-
ods section). Two separate experiments (A,
B, C and D, E, F) were carried out and each
experiment used three sham-operated rats
and three 5/6 nephrectomized rats. RNA sam-
ples loaded in each lane are indicated at the
top. Definitions are: Sham, total RNA isolated
from sham-operated rats; NR, total RNA iso-
lated from 5/6 nephrectomized rats.
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Fig. 6. Densitometric analysis of OAT-K1
(A) and OAT-K2 (B) mRNA expression in
sham-operated () and 5/6 nephrectomized
() rat kidneys using a FUJIX BIO-Imaging
Analyzer BAS 2000II (corrected according to
densitometry of GAPDH mRNA). Each point
represents the mean SE of six rats from two
separate experiments. **P 0.01, significantly
different from sham-operated rats.
for GAPDH mRNA. As shown in Figure 6, there were
no significant differences in the levels of OAT-K1 and
OAT-K2 mRNA expressions at one week after 5/6 ne-
phrectomy (ratios to GAPDH: OAT-K1, 0.49  0.08 in
the sham-operated rat kidney and 0.35  0.08 in the
remnant kidney, P 	 0.27; OAT-K2, 0.27  0.02 in the
sham-operated rat kidney and 0.36 0.07 in the remnant
kidney, P	 0.28). On the other hand, the levels of OAT-
K1 and OAT-K2 mRNA expressions were significantly
Fig. 7. RT-PCR (A) and Northern blot analysis (B) for SGLT1,decreased at two and four weeks after 5/6 nephrectomy SGLT2, MRP2 and GAPDH mRNA expressions in the renal total
RNA isolated from sham-operated and 5/6 nephrectomized rat kidneys(ratios to GAPDH: OAT-K1, 0.67  0.06 in the sham-
at two weeks after the surgery. (A) All of the PCR reactions wereoperated kidney and 0.12  0.04 in the remnant kidney
performed as described in the Methods section, using three sham-oper-
at two weeks, P 0.01, 0.69 0.18 in the sham-operated ated rats and three 5/6 nephrectomized rats. (B) Aliquots of 5 g of
total RNA from four sham-operated rats and four 5/6 nephrectomizedkidney and 0.12  0.03 in the remnant kidney at four
rats were electrophoresed, blotted, and hybridized with [-32P] probesweeks, P  0.01; OAT-K2, 0.48  0.04 in the sham- of each transporter at high stringency. Sham, total RNA isolated from
operated kidney and 0.21  0.05 in the remnant kidney sham-operated rats; 5/6 NR, total RNA isolated from 5/6 nephrecto-
mized rats.at two weeks, P 0.01, 0.35 0.03 in the sham-operated
kidney and 0.13  0.04 in the remnant kidney at four
weeks, P  0.01).
Methotrexate clearance in 5/6 nephrectomized rats
Detection of mRNA expression levels for several
To examine the changes in methotrexate clearanceorganic solute transporters localized in the
under renal failure when OAT-K1 and OAT-K2 mRNAbrush border membranes
expressions were markedly decreased, experiments were
Despite the fact that there were no pathological differ- performed two weeks after the surgery. As summarized
ences in tubules between sham-operated and 5/6 ne- in Table 2, plasma concentrations of methotrexate were
phrectomized rats (Fig. 2), the mRNA expression levels markedly elevated in 5/6 nephrectomized rats compared
of OAT-K1 and OAT-K2 were depressed two weeks with that in sham-operated rats throughout the experi-
after the surgery (Figs. 5 and 6). Therefore, two weeks ment. In addition, renal clearance of methotrexate in 5/6
after the surgery was chosen as the time point to examine nephrectomized rats was significantly decreased both at
whether mRNA expression levels of other transporters period 1 and period 2. Moreover, treatment with folinic
expressed in the renal brush-border membranes de- acid resulted in the reduction of plasma concentration
creased. By using semiquantitative RT-PCR (Fig. 7A) and enhanced renal clearance of methotrexate in sham-
and Northern blot analyses (Fig. 7B), we characterized operated rats (P  0.01), but it had no effect on the
the mRNA expression levels of SGLT1, SGLT2, and methotrexate renal clearance in 5/6 nephrectomized rats.
MRP2. The mRNA expression levels of SGLT1, SGLT2, The plasma unbound fraction of methotrexate was sig-
and MRP2 revealed no significant differences between nificantly higher in 5/6 nephrectomized rats than that in
sham-operated rats. Other features following 5/6 nephrec-in sham-operated rats and in 5/6 nephrectomized rats.
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Table 3. Effect of renal ablation on body weight, urine volume andTable 2. Pharmacokinetic parameters describing the renal handling
of methotrexate in sham-operated and 5/6 nephrectomized rats renal function two weeks after the surgery
Sham 5/6 NRPeriod 1 Period 2
Sham 5/6 NR Sham 5/6 NR Body weight g 2958.2 22212.7b
Urine volume mL/24 h 20.23.9 52.09.1b
Cpss lmol/L 1.210.09 2.400.32a 0.790.07b 2.400.35a Serum creatinine mg/dL 0.820.16 1.460.15a
Ctot mL/min 3.760.31 2.040.31a 5.840.53b 2.080.35a Urinary creatinine mg/dL 71.29.7 23.13.1b
Fu % 57.851.54 84.015.44a Creatinine clearance mL/min 1.100.18 0.480.08b
Cren mL/min 1.920.25 0.330.13a 3.160.35b 0.360.14a BUN mg/dL 18.50.86 73.39.84b
Serum albumin mg/dL 21518.8 1107.5bMethotrexate was infused intravenously at a rate of 4.4 nmol/min without
(period 1) or with (period 2) folinic acid infused simultaneously at a rate of 65 Urinary albumin mg/dL 6.41.9 327107a
nmol/min. Each number represents the mean  SE of six rats except for the
Rats were kept in metabolic cages for the last three days of a two-week periodplasma unbound fraction of methotrexate (Fu), which represents the mean 
after the surgery to collect urine samples. Plasma samples were collected justSE of three rats.
before the in vivo methotrexate clearance study. Each nymber represents theAbbreviations are: Sham, sham-operated rats; 5/6 NR, 5/6 nephrectomized
mean  SE of six rats. Abbreviations are: Sham, sham-operated rats; 5/6 NR,rats; Cpss, plateau plasma concentration; Ctot, total clearance; Fu, plasma un-
5/6 nephrectomized rats; BUN, blood urea nitrogen.bound fraction; Cren, reanal clearance. aP  0.05, bP  0.01, significantly different from sham-operated ratsaP  0.01, significantly different from sham-operated rats in each period
bP  0.01, significantly different from period 1
tomy used for the in vivo methotrexate clearance experi- in renal impairment is not well established. In general,
ments are summarized in Table 3. The body weight gain the dose of methotrexate is decreased proportionately
was smaller, creatinine clearance was lower, urine output to the decrease in creatinine clearance, but unexpected
was much greater, and serum albumin was lower in 5/6 side effects such as an excessively increased plasma con-
nephrectomized rats than those in sham-operated rats. centration and nephrotoxicity are often observed [1, 6].
Analysis of blood from sham-operated and 5/6 nephrec- Because methotrexate is excreted primarily into the
tomized rats revealed no significant differences in the urine, these effects may result from the alteration of
concentration of Na, K, Cl
, glucose, hematocrit, and renal handling of this drug. Among the factors possibly
hemoglobin among these rats (N	 4 to 7, for Na; 141 affecting the renal handling of methotrexate, the change
1.1 and 135  2.5 mmol/L, for K; 5.1  0.87 and 4.9  in expression levels of transporters mediating the tubular
0.37 mmol/L, for Cl
; 102  2.6 and 99  3.3 mmol/L, transport of methotrexate has been little studied.
for glucose; 120  7.1 and 125  6.4 mg/dL, for hemato- OAT-K1 and OAT-K2 were recently cloned in our
crit; 49  1.8% and 47  2.4%, for hemoglobin; 16  laboratory and defined to mediate methotrexate trans-
0.68 and 16  0.80 g/dL in sham-operated and 5/6 ne- port [16, 17]. Previous studies have shown that both
phrectomized rats, respectively). of them are expressed specifically in the brush-border
membranes of the proximal tubules and mediate bidirec-Methotrexate uptake by remnant kidney slices
tional transport of their substrates [17, 19]. Our current
To examine whether the accumulation of methotrex- study examined the changes in the methotrexate renal
ate from blood into proximal epithelial cells was changed clearance and mRNA expression levels of OAT-K1 and
in the 5/6 nephrectomized rat kidney, the accumulation OAT-K2 in the state of renal failure to clarify the phar-
of methotrexate by renal slices of the remnant kidneys macological significance of these transporters to the uri-
were studied two weeks after the renal ablation. There nary excretion of methotrexate.
were no significant differences in [3H]methotrexate accu- Using MDCK cells stably transfected with OAT-K1
mulation by renal slices from sham-operated and 5/6 and OAT-K2, methotrexate, folic acid, and folinic acid
nephrectomized rat kidneys (N 	 6, [3H]methotrexate were mutually exchanged via OAT-K1 and OAT-K2
concentration was 95.0  15.0 nmol/L in slices from
(Fig. 1), which was consistent with a previous report [20].
sham-operated rat kidney and 74.5 9.5 nmol/L in those
These results showed that both OAT-K1– and OAT-K2–from remnant kidneys; data were the mean  SE of six
mediated methotrexate efflux was accompanied by foli-independent animals for two separate experiments, and
nic acid exchange, suggesting that these transportersP 	 0.28 between sham-operated and 5/6 nephrecto-
could enhance the apical efflux of methotrexate accumu-mized rats).
lated in the tubular epithelial cells and contribute to
“folinic acid rescue” by exchanging intracellular metho-
DISCUSSION trexate for luminal folinic acid.
To induce renal insufficiency, a 5/6 nephrectomy wasIn renal impairment, the dosage regimen of drugs must
performed in rats. Renal ablation causes glomerular andbe modified because renal failure has a variety of in-
tubular hypertrophy, resulting in end-stage renal diseasefluences on pharmacokinetics and pharmacodynamics
[33]. First, we examined the morphological changes and[31, 32]. Despite a quarter century of clinical experience
with methotrexate, the ideal dosage regimen for this drug biochemical parameters in 5/6 nephrectomized rats one
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to four weeks after the surgery. The results indicated unilaterally nephrectomized rats [7]. The toxic effects of
a one-month repeated oral dose of methotrexate werethat 5/6 nephrectomy caused marked renal insufficiency
(Figs. 2 and 3), but morphological tubular damage was more severe in unilaterally nephrectomized rats than
those of sham-operated rats. It was suggested that thesenot so severe (Fig. 2).
The mRNA expression levels of OAT-K1 and OAT-K2 effects were caused by the longer exposure to metho-
trexate in unilaterally nephrectomized rats because of thegradually increased with age in the sham-operated rat
kidney. On the other hand, the expression levels of these decreased renal clearance. The present results could sug-
gest that the expression levels of OAT-K1 and OAT-K2transporters were markedly diminished two and four
weeks after renal ablation as compared to the sham- were decreased in these unilaterally nephrectomized rat
kidneys. Therefore, a problem may arise, that is, the inef-operated kidneys (Figs. 5 and 6). These results suggested
that progressive renal failure is accompanied by a marked fectiveness of folinic acid in patients treated with metho-
trexate therapy under condition of renal insufficiency.decrease in the expressions of OAT-K1 and OAT-K2. In
contrast, mRNA expression levels of other transporters A previous study indicated the delayed methotrexate
clearance and ineffective folinic acid rescue in a patientlocalized in the brush-border membranes of the proximal
tubules, SGLT1, SGLT2 [25, 34], and MRP2 [15] were with epidermoid carcinoma, treated with high-dose metho-
trexate therapy with folinic acid rescue accompanied bynot changed significantly by 5/6 nephrectomy (Fig. 7).
The unchanged expression level of SGLT1 mRNA was renal failure [37]. In addition, another study reported the
pharmacokinetics of a low dose of methotrexate in rheu-consistent with the report by Brooks et al [35], showing
a significantly reduced expression level of sodium phos- matoid arthritis patients with renal impairment [6]. Be-
cause of the high interindividual variability of the phar-phate cotransporter (NaPi-2) and unchanged SGLT1 in
5/6 nephrectomized rat kidneys. Therefore, reduced macokinetics of methotrexate, individual testing rather
than a general decrease of the methotrexate dose basedmRNA levels of OAT-K1 and OAT-K2 in the remnant
kidneys would be a specific response to reduced renal on creatinine clearance would be recommended. The
variations in pharmacokinetics of methotrexate undermass. In addition, the changes in expressions of aquaporin
water channels (AQP1, AQP2, AQP3) were studied at renal impairment are less defined, but changes in the ex-
pression of tubular drug transporters such as OAT-K1the mRNA and/or protein levels, and also were decreased
as NaPi-2 mRNA in the remnant kidney [36]. While these and OAT-K2 may contribute to these phenomena.
Because no significant differences (P	 0.28) in metho-channels and transporters contribute to maintaining ho-
meostasis of the body fluid, nutrients and electrolytes, trexate accumulation by renal slices were observed be-
tween remnant kidneys and sham-operated kidneys, theto our knowledge, the present study is the first report
evaluating the relationship between the expression levels extent of concentrative methotrexate accumulation should
be comparable between remnant kidneys and sham-oper-of renal drug transporters and the progression of renal
failure. However, the regulatory mechanism(s) of the ex- ated kidneys. However, a significant decrease in the renal
clearance of methotrexate under renal failure occurred,pression of OAT-K1 and OAT-K2 remains to be eluci-
dated. which is probably due to an altered methotrexate efflux
activity that resulted from the decreased expression levelsMethotrexate pharmacokinetics were dramatically al-
tered following renal failure (Table 2) and at markedly of OAT-K1 and OAT-K2. Considering the unchanged
mRNA levels of another organic anion efflux pump,decreased expression levels of OAT-K1 and OAT-K2
(Figs. 5 and 6). There was a marked increase in the plasma MRP2, which could mediate methotrexate transport at
the brush-border membranes of proximal tubular cellsmethotrexate concentration and a decrease in the metho-
trexate renal clearance, causing a longer exposure to other than OAT-K1 and OAT-K2, it is possible that
OAT-K1 and OAT-K2 play predominant roles in themethotrexate. In addition, the plasma unbound fraction
of methotrexate was significantly higher in 5/6 nephrec- tubular secretion of methotrexate.
In conclusion, the present study demonstrates thattomized rats than that in sham-operated rats (Table 2),
probably because of the reduced serum level and the OAT-K1– and OAT-K2–mediated methotrexate efflux
is stimulated by folinic acid exchange. In addition, weincreased urinary loss of albumin in 5/6 nephrectomized
rats (Table 3). Moreover, the beneficial effects of folinic found marked reductions in the mRNA expression levels
of OAT-K1 and OAT-K2 in the remnant kidneys afteracid such as enhancement of methotrexate secretion in
sham-operated rats, “folinic acid rescue,” disappeared 5/6 nephrectomy, when longer exposure to methotrexate
and ineffectiveness of folinic acid against methotrexatein 5/6 nephrectomized rats (Table 2). These results sug-
gest that the depressed levels of OAT-K1 and OAT-K2 secretion occurs. These results suggest that OAT-K1 and
OAT-K2 play a predominant role in the renal secretioncause the decreased renal excretion of methotrexate,
which results in the longer exposure to methotrexate of methotrexate, and are responsible for the beneficial
effects of folinic acid in accelerating excretion of accumu-and ineffectiveness of folinic acid rescue in 5/6 nephrec-
tomized rats. Similar findings were recently reported in lated methotrexate. These findings provide important
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brane of kidney proximal tubules. J Am Soc Nephrol 8:1213–1221,information regarding the appropriate usage of metho-
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glomerular filtration rate but also on the changes in ex- 17. Masuda S, Ibaramoto K, Takeuchi A, et al: Cloning and functional
characterization of a new multispecific organic anion transporter,pression levels of OAT-K1 and OAT-K2.
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